Aligos Therapeutics (ALGS) Research & Development (2021 - 2025)
Historic Research & Development for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $23.9 million.
- Aligos Therapeutics' Research & Development rose 4270.3% to $23.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.4 million, marking a year-over-year decrease of 1052.34%. This contributed to the annual value of $70.3 million for FY2024, which is 379.38% down from last year.
- According to the latest figures from Q3 2025, Aligos Therapeutics' Research & Development is $23.9 million, which was up 4270.3% from $14.0 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Research & Development ranged from a high of $31.7 million in Q1 2022 and a low of $14.0 million during Q2 2025
- For the 5-year period, Aligos Therapeutics' Research & Development averaged around $20.3 million, with its median value being $18.1 million (2023).
- As far as peak fluctuations go, Aligos Therapeutics' Research & Development tumbled by 4274.85% in 2023, and later surged by 4270.3% in 2025.
- Quarter analysis of 5 years shows Aligos Therapeutics' Research & Development stood at $28.6 million in 2021, then tumbled by 33.21% to $19.1 million in 2022, then increased by 16.53% to $22.3 million in 2023, then fell by 27.97% to $16.0 million in 2024, then soared by 49.32% to $23.9 million in 2025.
- Its Research & Development stands at $23.9 million for Q3 2025, versus $14.0 million for Q2 2025 and $14.5 million for Q1 2025.